Selenium, calcium channel blockers, and cancer risk - The Yin and Yang of apoptosis?

Medical Hypotheses

Volumn 50, Issue 5, 1998, Pages 423-433

  McCarty, M F ^a  

^a Nutrition 21 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; SELENIUM;

APOPTOSIS; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; DIETARY FIBER; GENOTOXICITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL;

EID: 0031777425     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(98)90216-X     Document Type: Article

References (170)

1. Simic M G, Grossman L, Upton A C, eds. Mechanisms of DNA Damage and Repair: Implications for Carcinogenesis and Risk Assessment. New York: Plenum Press, 1986.
2. Bishop J M. Molecular themes in oncogenesis. Cell 1991; 64: 235-248.
3. Carson D A, Ribeiro J M. Apoptosis and disease. Lancet 1993; 341: 1251-1254.
4. Fisher D E. Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 78: 539-542.
5. Kerr J F R, Winterford C M, Harmon B V. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-2026.
6. Arends M J, McGregor A H, Wyllie A H. Apoptosis is inversely related to necrosis and determines net growth in tumors bearing constitutively expressed myc, ras, and HPV oncogenes. Am J Pathol 1994; 144: 1045-1057.
7. Schulte-Herrnann R, Timmermann-Trosiener I, Barthel G, Bursch W. DNA synthesis, apoptosis, and phenotypic expression as determinants of growth of altered foci in rat liver during phenobarbital promotion. Cancer Res 1990; 50: 5127-5135.
8. Bursch W, Oberhammer F, Schulte-Hermann R. Cell death by apoptosis and its protective role against disease. Trends Pharm Sci 1992; 13: 245-251.
9. Schulte-Herrnann R, Bursch W, Grasl-Kraupp B et al. Role of active cell death (apoptosis) in multi-stage carcinogenesis. Toxicol Lett 1995; 82/83: 143-148.
10. Wright S C, Zhong J, Larrick J W. Inhibition of apoptosis as a mechanism of tumor promotion. FASEB J 1994; 8: 654-660.
11. Tomei L D, Kanter P, Wenner C E. Inhibition of radiation-induced apoptosis in vitro by tumor promoters. Biochem Biophys Res Comm 1988; 55: 324-331.
12. McConkey D J, Hartzell P, Jondal M, Orrenius S. Inhibition of DNA fragmentation in thymocytes and isolated thymocyte nuclei by agents that stimulate protein kinase C. J Biol Chem 1989; 264: 13399-13402.
13. Rodríguez-Tarduchy G, López-Rivas A. Phorbol esters inhibit apoptosis in IL-2-dependent T lymphocytes. Biochem Biophys Res Comm 1989; 164: 1069-1075.
14. Lotern J, Cragoe E J Jr, Sachs L. Rescue from programmed cell death in leukemic and normal myeloid cells. Blood 1991; 78: 953-960.
15. + antiporter in suppression of apoptosis by granulocyte macrophage colony-stimulating factor and interleukin-3. J Biol Chem 1992; 267: 9980-9987.
16. Haimovitz-Friedman A, Balaban N, McLoughlin M et al. Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis. Cancer Res 1994; 54: 2591-2597.
17. Piacentini M, Annicchiarico-Petruzzelli M, Oliverio S et al. Phenotype specific 'tissue' transglutaminase regulation in human neuroblastoma cells in response to retinoic acid: correlation with cell death by apoptosis. Int J Cancer 1992; 52: 271-278.
18. Kalemkerian G P, Slusher R, Ramalingam S et al. Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines. J Natl Cancer Inst 1995; 87: 1674-1680.
19. Lotan R. Retinoids and apoptosis: implications for cancer chemoprevention and therapy. J Natl Cancer Inst 1995; 87: 1655-1657.
20. 1 mice. Cancer Res 1994; 54: 5508-5510.
21. Grasl-Kraupp B, Bursch W, Ruttkay-Nedecky B et al. Food restriction eliminates preneoplastic cells through apoptosis and antagonizes carcinogenesis in rat liver. Proc Natl Acad Sci USA 1994; 91: 9995-9999.
22. Sell C, Baserga R, Rubin R. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res 1995; 55: 303-306.
23. Resnicoff M, Abraham D, Yutanawiboonchi W et al. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 1995; 55: 2463-2469.
24. Yeoh S I, Baxter R C. Metabolic regulation of the growth hormone independent insulin-like growth factor binding protein in human plasma. Acta Endocrinol 1988; 119: 465-473.
25. Parr T. Insulin exposure controls the rate of mammalian aging. Mech Ageing Dev 1996; 88: 75-82.
26. McCarty M F. Up-regulation of IGF binding protein-1 as an anticarcinogenic strategy - relevance to caloric restriction, exercise, and insulin sensitivity. Med Hypotheses 1997; 48: 297-308
27. Clayton C C, Baumann C A. Diet and azo dye tumors: effect of diet during a period when the dye is not fed. Cancer Res 1949; 9: 575-582.
28. Shamberger R J. Relationship of selenium to cancer, I: inhibitory effect of selenium on carcinogenesis. J Natl Cancer Inst 1970; 44: 931-936.
29. Griffin A C. Role of selenium in the chemoprevention of cancer. Adv Cancer Res 1979; 29: 419-442 .
30. 3H/St mice. Carcinogenesis 1980; 1: 199-201.
31. Ip C. Prophylaxis of mammary neoplasia by selenium supplementation in the initiation and promotion phases of chemical carcinogenesis. Cancer Res 1981; 41: 4386-4390.
32. Combs G F Jr, Clark L C. Can dietary selenium modify cancer risk? Nutr Rev 1985; 43: 325-331.
33. Ip C. The chemopreventive role of selenium in carcinogenesis. J Am Coll Toxicol 1986; 5: 7-20.
34. Burke K E, Combs G F Jr, Gross E G et al. The effects of topical and oral L-selenomethionine on pigmentation and skin cancer induced by ultraviolet irradiation. Nutr Cancer 1992; 17: 123-137.
35. Knizhnikov V A, Shandala N K, Komleva V A et al. The effect of dietary levels of selenium on radiation resistance and radiation-induced carcinogenesis. Nutr Res 1996; 16: 505-516.
36. Ip C, Hayes C, Budnick R M, Ganther H E. Chemical form of selenium, critical metabolites, and cancer prevention. Cancer Res 1991; 51: 595-600.
37. Lawson T, Birt D F. Enhancement of the repair of carcinogen-induced DNA damage in the hamster pancreas by dietary selenium. Chem-Biol Interact 1983; 45: 95-104.
38. Lu J X, Jiang C, Ganther H E. Species specific induction of DNA fragmentation typical of apoptotic cell death by selenium. Proc Am Assoc Cancer Res 1993; 34: 291.
39. Thompson H J, Wilson A, Lu J et al. Comparison of the effects of an organic and an inorganic form of selenium on a mammary carcinoma cell line. Carcinogenesis 1994; 15: 183-186.
40. Lanfear J, Fleming J, Wu L et al. The selenium metabolite selenodiglutathione induces p53 and apoptosis: relevance to the chemopreventive effects of selenium? Carcinogenesis 1994; 15: 1387-1392.
41. Redman C, Xu M J, Peng Y M et al. Involvement of polyamines in selenomethionine induced apoptosis and mitotic alterations in human tumor cells. Carcinogenesis 1997; 18(6): 1195-1202.
42. Wilson A C, Thompson J H, Schedin P J et al. Effect of methylated forms of selenium on cell viability and induction of DNA strand breakage. Biochem Pharmacol 1992; 43: 1137-1141.
43. Pahor M, Guralnik J M, Ferrucci L et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996; 348: 493-497.
44. Connor J, Sawczuk I S, Benson M C et al. Calcium channet antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. Prostate 1988; 13: 119-130.
45. 2+ channels exposed to serum from patients with type I diabetes. Science 1993; 261: 86-90.
46. 2+ antagonists inhibit DNA fragmentation and toxic cell death induced by acetaminophen. FASEB J 1993; 7: 453-463.
47. McConkey D J, Hartzell P, Nicotera P, Orrenius S. Calcium-activated DNA fragmentation kills immature thymocytes. FASEB J 1989; 3: 1843-1849.
48. Vandewalle B, Hornez L, Wattez N et al. Vitamin-D3 derivatives and breast-tumor cell growth: effect on intracellular calcium and apoptosis. Int J Cancer 1995; 61: 806-811.
49. Trump B F, Berezesky I K. Calcium-mediated cell injury and cell death. FASEB J 1995; 9: 219-228.
50. Cohen J J, Duke R C. Glucorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J Immunol 1984; 132: 38-42.
51. Clark L C, Combs G R Jr, Turnbull B W et al. The nutritional prevention of cancer with selenium 1983-1993: a randomized clinical trial. J Am Med Assoc 1996; 276: 1957-1963.
52. Yu S-Y, Zhu Y-J, Li W-G et al. A preliminary report on the intervention trials of primary liver cancer in high-risk populations with nutritional supplementation of selenium in China. Biol Trace Elem Res 1991; 29: 289-294.
53. Yu S-Y, Chu Y-J, Gong X-L et al. Regional variation of cancer mortality incidence and its relation to selenium levels in China. Biol Trace Elem Res 1985; 7: 21-29.
54. Blot W J, Li J-Y, Taylor P R et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/ mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993; 85: 1483-1492.
55. Pienta K J, Nguyet N M, Lehr J E. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res 1993; 52: 224-226.
56. Formelli F, Clerici M, Campa T et al. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 1993; 11: 2036-2042.
57. Costa A, Formelli F, Chiesa F et al. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res 1994; 54(Suppl.): 2032S-2037S.
58. Garewal H. Antioxidants in oral cancer prevention. Am J Clin Nutr 1995; 62(Suppl.): 1410S-1416S.
59. Meyskens F L Jr, Manetta A. Prevention of cervical intraepithelial neoplasia and cervical cancer. Am J Clin Nutr 1995; 62(Suppl): 1417S-1419S.
60. Bertram J S. Inhibition of chemically induced neoplastic transformation by carotenoids. Ann NYAcad Sci 1993; 691: 161-175.
61. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-1035.
62. Marwick C. Trials reveal no benefit, possible harm of beta carotene and vitamin A for lung cancer prevention. J Am Med Assoc 1996; 275: 422-423.
63. Levy J, Bosin E, Feldman B et al. Lycopene is a more potent inhibitor of human cancer cell proliferation than either α-carotene or β-carotene. Nutr Cancer 1995; 24: 257-266.
64. Werner H, LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 1996; 68: 183-223.
65. Lønning P E, Hall K, Aakvaag A, Lien E A. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res 1992; 52: 4719-4723.
66. Lahti E I, Knip M, Laatikainen T J. Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long-term tamoxifen. Cancer 1994; 74: 618-624.
67. Liu L, Brinkman A, Blat C, Harel L. IGFBP-1, an insulin like growth factor binding protein, is a cell growth inhibitor. Biochem Biophys Res Commun 1991; 174: 673-679.
68. Yee D, Jackson J G, Kozelsky T W, Figueroa J A. Insulin-like growth factor binding protein 1 expression inhibits insulin-like growth factor I action in MCF-7 breast cancer cells. Cell Growth Diff 1994; 5: 73-77.
69. Figueroa J A, Sharma J, Jackson J G et al. Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells. J Cell Physiol 1993; 157: 229-236.
70. Pietrzkowski Z, Wernicke D, Porcu P et al. Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1. Cancer Res 1992; 52: 6447-6451.
71. Pietrzkowski Z, Mulholland G, Gomella L et al. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 1993; 53: 1102-1106.
72. Lamberts S W J, Koper J W, Reubi J-C. Potential role of somatostatin analogues in the treatment of cancer. Eur J Clin Invest 1987; 17: 281-287.
73. Schally A V. Oncological applications of somatostatin analogues. Cancer Res 1988; 48: 6977-6985.
74. Parmer H, Bogden A, Mollard M et al. Somatostatin and somatostatin analogues in oncology. Cancer Treat Rev 1989; 16: 95-115.
75. Choe M, Kris E S, Luthra R et al. Protein kinase C is activated and diacylglycerol is elevated in epidermal cells from Sencar mice fed high fat diets. J Nutr 1992; 122: 2322-2329.
76. Chapkin R S, Gao J, Lee D-Y K, Lupton J R. Dietary fibers and fats alter rat colon protein kinase C activity: correlation to cell proliferation. J Nutr 1993; 123: 649-655.
77. Birt D F, Kris E S, Choe M, Pelling J C. Dietary energy and fat effects on tumor promotion. Cancer Res 1992; 52(Suppl.): 2035S-2039S.
78. Tran K, Proulx P R, Chan A C. Vitamin E suppresses diacylglycerol (DAG) level in thrombin-stimulated endothelial cells through an increase of DAG kinase activity. Biochim Biophys Acta 1994; 1212: 193-202.
79. Lee I-K, Koya D, Ishii H, King G L. Vitamin E (vit E) prevents the hyperglycemia induced activation of diacylglycerol (DAG)-protein kinase C (PKC) pathway in vascular smooth muscle cell by an increase of DAG kinase activity. Diabetes 1996; 45(Suppl. 2): 64A.
80. Koya D, Lee I-K, Ishii H, Busell S-E. Vitamin E normalized glomerular hyperfiltration and protein kinase C activation by increasing diacylglycerol kinase in diabetic rats. Diabetes 1996; 45(Suppl. 2): 205A.
81. Marsh J B, Topping D L, Nestel P J. Comparative effects of dietary fish oil and carbohydrate on plasma lipids and hepatic activities of phosphatidate phosphohydrolase, diacylglycerol acyltransferase and neutral lipase activities in the rat. Biochim Biophys Acta 1987; 922: 239-243.
82. Surette M E, Whelan J, Broughton K S, Kinsella J E. Evidence for mechanisms of the hypotriglyceridemic effect of n-3 polyunsaturated fatty acids. Biochim Biophys Acta 1992; 1126: 199-205.
83. McCarty M F. Nitric oxide deficiency, leukocyte activation, and resultant ischemia are crucial to the pathogenesis of diabetic retinopathy/neuropathy - preventive potential of antioxidants, essential fatty acids, chromium, ginkgolides, and pentoxifylline. Medical Hypotheses 1998; 50: 435-449.
84. Couldwell W T, Hinton D R, He S et al. Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett 1994; 345: 43-46.
85. Knox K A, Finney M, Milner A E et al. Second-messenger pathways involved in the regulation of survival in germinal-centre B cells and in Burkitt lymphoma lines. Int J Cancer 1992; 52: 959-966.
86. Couldwell W T, Weiss M H, DeGiorgio C M et al. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 1993; 32: 485-490.
87. Baltuch G, Shenouda G, Langleben A, Villemure J-G. High dose tamoxifen in the treatment of recurrent high grade glioma: a report of clinical stabilization and tumour regression. Can J Neurol Sci 1993; 20: 168-170.
88. O'Brian C A, Liskamp R M, Solomon D H, Weinstein I B. Inhibition of protein kinase C by tamoxifen. Cancer Res 1985; 45: 2462-2465.
89. Horgan K, Cooke E, Hallett M B, Mansel R E. Inhibition of protein kinase C mediated signal transduction by tamoxifen. Biochem Pharm 1986; 35: 4463-4465.
90. McClay E F, McClay M E T. Tamoxifen: is it useful in the treatment of patients with metastic melanoma? J Clin Oncol 1994; 12: 617-626.
91. Roig L M V, Lotfi H, Olcese J E et al. Effects of short-term tamoxifen administration in patients with invasive cervical carcinoma. Anticancer Res 1993; 13: 2457-2464.
92. Farinati F, De Maria N, Fornasiero A et al. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Digest Dis Sci 1992; 37: 659-662.
93. Meyer T, Regenass U, Fabbro D et al. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int J Cancer 1989; 43: 851-856.
94. Barry M A, Reynolds J E, Eastman A. Etoposide-induced apoptosis in human HL-60 cells is associated with intracellular acidification. Cancer Res 1993; 53: 2349-2357.
95. Li J, Eastman A. Apoptosis in an interleukin-2-dependent cytotoxic T lymphocyte cell line is associated with intracellular acidification. J Biol Chem 1995; 270: 3203-3211.
96. Pérez-Sala D, Collado-Escobar D, Mollinedo F. Intracellular alkalinization suppresses lovastatin-induced apoptosis in HL-60 cells through the inactivation of a pH-dependent endonuclease. J Biol Chem 1995; 270: 6235-6242.
97. + exchange in human neutrophils by analogues of amiloride: structure-activity relationships in the amiloride series. Molec Pharm 1986; 30: 112-120.
98. Maidorn R P, Cragoe E J Jr, Tannock I F. Therapeutic potential of analogues of amiloride: inhibition of the regulation of intracellular pH as a possible mechanism of tumour selective therapy. Br J Cancer 1993; 67: 297-303 .
99. Sparks R L, Pool T B, Smith N K R, Cameron I L. Effects of amiloride on tumor growth and intracellular element content of tumor cells in vivo. Cancer Res 1983; 43: 73-77.
100. Fesus L, Davies P J A, Piacentini M. Apoptosis: molecular mechanisms in programmed cell death. Eur J Cell Biol 1991; 56: 170-177.
101. Ueda N, Shah S V. Apoptosis. J Lab Clin Med 1994; 124: 169-177.
102. Peterson G, Barnes S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 1993; 22: 335-345.
103. Crowell P L, Gould M N. Chemoprevention and therapy of cancer by d-limonene. Crit Rev Oncogen 1994; 5: 1-22.
104. Crowell P L, Chang R R, Ren Z et al. Selective inhibition of isoprenylation of 21-26 kDa proteins by the anticarcinogen d-limonene and its metabolites. J Biol Chem 1991; 266: 17,679-17,685.
105. Barnes S. Effect of genistein on in vitro and in vivo models of cancer. J Nutr 1995; 125: 777S-783S .
106. Fotsis T, Pepper M, Adlercreutz H et al. Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J Nutr 1995; 125: 790S-797S.
107. Yanagihara K, Ito A, Toge T, Numoto M. Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract. Cancer Res 1993; 53: 5815-5821.
108. Elson C E, Maltzman T H, Boston J L et al. Anticarcinogenic activity of d-limonene during the initiation and promotion/ progression stages of DMBA-induced rat mammary carcinogenesis. Carcinogenesis 1988; 9: 331-332.
109. Maltzman T H, Hurt L M, Elson C E et al. The prevention of nitrosomethylurea-induced mammary tumors by d-limonene and orange oil. Carcinogenesis 1989; 10: 781-783.
110. Elegbede J A, Elson C E, Qureshi M A et al. Inhibition of DMBA-induced mammary cancer by the monoterpene d-limonene. Carcinogenesis 1984; 5: 661-664.
111. Haag J D, Linstrom M J, Gould M N. Limonene-induced regression of mammary carcinomas. Cancer Res 1992; 52: 4021-4026.
112. Messina M J, Persky V, Setchell K D R, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994; 21: 113-131.
113. Herman C, Adlercreutz T, Goldin B R et al. Soybean phytoestrogen intake and cancer risk. J Nutr 1995; 125: 757S-770S.
114. Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 1993; 342: 1209-1210.
115. Morton M S, Wilcox G, Wahlqvist M L, Griffiths K. Determination of lignans and isoflavonoids in human female plasma following dietary supplementation. J Endocrinol 1994; 142: 251-259.
116. Steele V E, Pereira M A, Sigman C C, Kelloff G J. Cancer chemoprevention agent development strategies for genistein. J Nutr 1995; 125: 713S-716S.
117. Hannun Y A, Obeid L M. Ceramide: an intracellular signal for apoptosis. Trends Biochem Sci 1995; 20: 73-77.
118. Welsh J, Simboli-Campbell M, Narvaez C J, Tenniswood M. Role of apoptosis in the growth inhibitory effects of vitamin D in MCF-7 cells. In: Diet and Cancer. New York: American Institute for Cancer Research / Plenum Press, 1995: 45-52.
119. American Cancer Society. Coley's mixed toxins or mixed bacterial toxins (MBT). In: Unproven Methods of Cancer Management. New York: American Cancer Society, 1971: 61-63.
120. Garland C F, Comstock G W, Garland F C et al. Serum 25-hydroxy-vitamin D and colon cancer: eight-year prospective study. Lancet 1989; 2: 1176-1178.
121. Schwartz G G, Hulka B S. Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis). Anticancer Res 1990; 10: 1307-1312.
122. Hanchette C L, Schwartz G G. Geographic patterns of prostate cancer mortality: evidence for a protective effect of ultraviolet radiation. Cancer 1992; 70: 2861-2869.
123. Feldman D, Skowronski R J, Peehl D M. Vitamin D and prostate cancer. In: Diet and Cancer. New York: American Institute for Cancer Research/Plenum Press, 1995: 53-63.
124. 3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism. Blood 1991; 78: 75-82.
125. Anzano M A, Smith J M, Uskokovic C W et al. 1α,25-dihydroxy-16-ene-23yne-26,27-hexafluorocholecalciferol (Ro24-5531) a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res 1994; 54: 1653-1656.
126. Colston K W, Mackay A G, Chander S et al. Novel vitamin D analogues suppress tumor growth in vivo. In: Vitamin D: Gene Regulation, Structure-Function Analysis and Clinical Application, Proceedings of the Eighth Workshop of Vitamin D. Berlin: de Gruyter, 1991: 465-474.
127. Brenner R V, Shabahang M, Schumaker L M et al. The antiproliferative effect of vitamin D analogs on MCF-7 human breast cancer cells. Cancer Lett 1995; 92: 77-82.
128. Galili U, Leizerowitz R, Moreb J et al. Metabolic and ultrastructural aspects of the in vitro lysis of chronic lymphocytic leukemia cells by glucocorticoids. Cancer Res 1982; 42: 1433-1440.
129. Bansal N, Houle A, Melnykovych G. Apoptosis: mode of cell death induced in T cell leukemia lines by dexamethasone and other agents. FASEB J 1991; 5: 211-216.
130. Barry M A, Behnke C, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharm 1990; 40: 2353-2362.
131. Harmon B V, Corder A M, Collins R J et al. Cell death induced in a murine mastocytoma by 42-47°C heating in vitro: evidence that the form of death changes from apoptosis to necrosis above a critical heat load. Int J Radiat Biol 1990; 58: 845-858.
132. Yonezawa M, Otsuka T, Matsui N et al. Hyperthermia induces apoptosis in malignant fibrous histiocytoma cells in vitro. Int J Cancer 1996; 66: 347-351.
133. Streffer C, Van Beuningen D. The biological basis for tumour therapy by hyperthermia and radiation. Recent Results Cancer Res 1987; 104: 24-70.
134. McCarty M F. Synergistic denaturant therapy - a general strategy for treatment of solid malignancies. Med Hypotheses 1980; 6: 1009-1034.
135. Katiyar S K, Agarwal R, Mukhtar H. Green tea in chemoprevention of cancer. Comprehen Ther 1992; 18: 3-8.
136. Conney A H, Wang Z-Y, Huang M-T et al. Inhibitory effect of green tea on tumorigenesis by chemicals and ultraviolet light. Prev Med 1992; 21: 361-369.
137. Agarwal R, Katiyar S K, Zaidi S I A, Mukhtar H. Inhibition of skin tumor promoter-caused induction of epidermal ornithine decarboxylase in SENCAR mice by polyphenolic fraction isolated from green tea and its individual epicatechin derivatives. Cancer Res 1992; 52: 3582-3588.
138. Oguni I, Nasu K, Yamamoto S, Nomura T. On the antitumor activity of fresh green tea leaf. Agric Biol Chem 1988; 52: 1879-1880.
139. Wang Z Y, Huang M-T, Ho C-T et al. Inhibitory effect of green tea on the growth of established skin papillomas in mice. Cancer Res 1992; 52: 6657-6665.
140. Oguni I, Cheng S J, Lin P Z, Hara Y. Protection against cancer risk by Japanese green tea. Prev Med 1992; 21: 331-333.
141. Gao Y T, McLaughlin J K, Blot W J et al. Reduced risk of esophageal cancer associated with green tea consumption. J Natl Cancer Inst 1994; 86: 855-858.
142. Onho Y, Wakai K, Genka K et al. Tea consumption and lung cancer risk: a case-control study in Okinawa, Japan. Jpn J Cancer Res 1995; 86: 1027-1034.
143. Hague A, Manning A M, Hanlon K A et al. Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer. Int J Cancer 1993; 55: 495-505.
144. Heerdt B G, Houston M A, Augenlicht L H. Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res 1994; 54: 3288-3294.
145. Boffa L C, Lupton J R, Mariani M R et al. Modulation of colonic epithelial-cell proliferation, histone acetylation, and luminal short-chain fatty acids by variation of dietary fiber (wheat bran) in rats. Cancer Res 1992; 52: 5906-5912.
146. Burkitt D P. Epidemiology of cancer of the colon and rectum. Cancer 1971; 28: 3-13.
147. Howe G R, Benito E, Castelleto R et al. Dietary intake of fiber and decreased risk of cancers of the colon and rectum: evidence from the combined analysis of 13 case-control studies. J Natl Cancer Inst 1992; 84: 1887-1896.
148. Kochi M, Takeuhi S, Mizutani T et al. Antitumor activity of benzaldehyde. Cancer Treat Rep 1980; 64: 21-23.
149. Kochi M, Isono N, Niwayama M, Shirakabe K. Antitumor activity of a benzaldehyde derivative. Cancer Treat Rep 1985; 89: 533-537.
150. Kochi M, Ueda S, Hagiwara T. Antitumor activity of sodium benzylideneascorbate. In: Bresciani F, King R J B, Lippman M E, Raynaud J-P, eds. Progress in Cancer Research and Therapy, Vol. 35: Hormones and Cancer 3. New York: Raven Press, 1988: 338-343.
151. Tatsumura T, Tsujimoto M, Koyama S et al. 4,6-0-Benzylidene-D-glucopyranose (BG) in the treatment of solid malignant tumours, an extended phase I study. Br J Cancer 1990; 62: 436-439.
152. Sakagami H, Asano K, Fukuchi K et al. Induction of tumor degeneration by sodium benzylideneascorbate. Anticancer Res 1991; 11: 1533-1538.
153. Takeuchi S, Kochi M, Sakaguchi K et al. Benzaldehyde as a carcinostatic principle in figs. Agric Biol Chem 1978; 42: 1449-1451.
154. Taetle R, Howell S B. Preclinical re-evaluation of benzaldehyde as a chemotherapeutic agent. Cancer Treat Rep 1983; 67: 561-566.
155. Pettersen E O, Schwarze P E, Dornish J M, Nesland J M. Antitumour effect of benzylidene-glucose (BG) in rats with chemically induced hepatocellular carcinoma. Anticancer Res 1986; 6: 147-152.
156. Tanuma S, Shiokawa D, Tanimoto Y et al. Benzylideneascorbate induces apoptosis in L929 tumor cells. Biochem Biophys Res Commun 1993; 194: 29-35.
157. McCarty M F. Cytostatic and reverse-transforming therapies of cancer - a brief review and future prospects. Med Hypotheses 1982; 8: 589-612.
158. Dernier G B. The Immortal Cell: Why Cancer Research Fails. New York: Avery Publishing Group, 1994.
159. Miller E E, Evans A E, Cohn M. Inhibition of rate of tumor growth by creatine and cyclocreatine. Proc Natl Acad Sci USA 1993; 90: 3304-3308.
160. Greenhaff P L, Casey A, Short A H et al. Influence of oral creatine supplementation of muscle torque during repeated bouts of maximal voluntary exercise in man. Clin Sci 1993; 84: 565-571.
161. Ohira Y, Inoue N. Effects of creatine and β-guanidinopropionic acid on the growth of Ehrlich ascites tumor cells: i.p. injection and culture study. Biochim Biophys Acta 1995; 1243: 367-372.
162. American Cancer Society. Krebiozen and carcalon. In: Unproven Methods of Cancer Management. New York: American Cancer Society, 1971: 135-138.
163. Brandes L J, Arron R J, Bogdanovic R P et al. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res 1992; 52: 3796-3800.
164. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972; 175: 409-416.
165. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? - G.H.A. Clowes Memorial Award Lecture. Cancer Res 1986; 46: 467-473.
166. Yamaoka M, Yamamoto T, Masadi T et al. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloro-acetyl-carbamoyl)fumagillol (TNP-470; AGM-1470). Cancer Res 1993; 53: 4262-4267.
167. 3 for angiogenesis. Science 1994; 264: 569-571.
168. D'Amato R J, Loughnan M S, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085.
169. McCarty M F. Fish oil may impede tumour angiogenesis and invasiveness by down-regulating protein kinase C and modulating eicosanoid production. Med Hypotheses 1996; 46: 107-115.
170. McCarty M F. Thalidomide may impede cell migration in primates by down-regulating integrin β-chains - potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. Med Hypotheses 1997; 49: 123-131.